Literature DB >> 20642556

The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Daniel F B Wright1, Evan J Begg.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: The clearance of many drugs is reduced in the elderly, but the data regarding phenytoin are conflicting. Most studies have estimated phenytoin metabolic clearance using total drug concentrations (bound plus unbound), which may be confounded by protein binding effects. Free phenytoin concentrations are independent of protein binding and should more accurately reflect true metabolic clearance changes in elderly patients. WHAT THIS STUDY ADDS: The two studies reported in this paper suggest a trend towards reduced free phenytoin 'apparent clearance' in the elderly, although statistically significant results were not found. Other published studies have largely found similar trends, suggesting an age effect. AIMS: To test the hypothesis that the 'apparent clearance' of free phenytoin is reduced in elderly patients.
METHODS: Two separate studies were conducted comparing free phenytoin 'apparent clearance' in elderly vs. younger adults. The first study was a retrospective analysis of free phenytoin concentrations measured at Christchurch Hospital from 1997 to 2006. In the second study free phenytoin concentrations were measured prospectively in ambulatory subjects who were taking phenytoin regularly.
RESULTS: In the retrospective study (n= 29), free phenytoin 'apparent clearance' was 0.27 +/- 0.04 l kg(-1) day(-1) (95% CI 0.19, 0.34) in the elderly cohort vs. 0.37 +/- 0.06 l kg(-1) day(-1) (95% CI 0.22, 0.52) in younger adults, but the difference was not statistically significant. In the prospective study, free phenytoin 'apparent clearance' showed a non-significant trend to being reduced in the elderly patients (0.12 +/- 0.02 l kg(-1) day(-1), 95% CI 0.07, 0.17) compared with the younger cohort (0.18 +/- 0.07 l kg(-1) day(-1), 95% CI 0.09, 0.26) in those not taking interacting drugs (n= 21).
CONCLUSIONS: This research does not prove the hypothesis that the 'apparent clearance' of free phenytoin is reduced in the elderly. However, the trends found in these two studies are supported by trends in the same direction in other published studies, suggesting an age effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20642556      PMCID: PMC2909816          DOI: 10.1111/j.1365-2125.2010.03673.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  42 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Changes in plasma protein binding have little clinical relevance.

Authors:  Leslie Z Benet; Betty-ann Hoener
Journal:  Clin Pharmacol Ther       Date:  2002-03       Impact factor: 6.875

3.  Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.

Authors:  Dina Battino; Danilo Croci; Daniela Mamoli; Sara Messina; Emilio Perucca
Journal:  Epilepsy Res       Date:  2004 Apr-May       Impact factor: 3.045

4.  Phenytoin dosage in the elderly.

Authors:  D C Lambie; F I Caird
Journal:  Age Ageing       Date:  1977-08       Impact factor: 10.668

5.  Effects of age, sex, obesity, and pregnancy on plasma diphenylhydantoin levels.

Authors:  A L Sherwin; J S Loynd; G W Bock; C D Sokolowski
Journal:  Epilepsia       Date:  1974-12       Impact factor: 5.864

6.  Changes in drug metabolism with increasing age: 2. phenytoin clearance and protein binding.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

7.  Effect of age, height, weight and sex on serum phenytoin concentration in epileptic patients.

Authors:  G W Houghton; A Richens; M Leighton
Journal:  Br J Clin Pharmacol       Date:  1975-06       Impact factor: 4.335

8.  Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.

Authors:  Chin-Chuan Hung; Chun-Jung Lin; Chih-Chuan Chen; Chee-Jen Chang; Horng-Huei Liou
Journal:  Ther Drug Monit       Date:  2004-10       Impact factor: 3.681

9.  Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.

Authors:  J E Ahn; J C Cloyd; R C Brundage; S E Marino; J M Conway; R E Ramsay; J R White; L C Musib; J O Rarick; A K Birnbaum; I E Leppik
Journal:  Neurology       Date:  2008-07-01       Impact factor: 9.910

10.  Plasma protein binding of drugs as a function of age in adult human subjects.

Authors:  A D Bender; A Post; J P Meier; J E Higson; G Reichard
Journal:  J Pharm Sci       Date:  1975-10       Impact factor: 3.534

View more
  1 in total

Review 1.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.